Sarepta Therapeutics Jumps 8.6% Amid Sector-Wide Rally
Sarepta Therapeutics (SRPT) saw an 8.6% increase in its stock price, closing at $19.57 amidst a broad rally in the biotechnology sector. This surge was not driven by company-specific news but rather by a sector-wide advance that also saw gains in several peer companies, suggesting a general rotation of investor interest into biotech. Investors are advised to monitor whether this sector momentum is sustainable and to observe volume trends and any divergence between Sarepta and its peers in upcoming trading sessions.
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2% - Here's Why
Sarepta Therapeutics (NASDAQ:SRPT) shares increased by 9.2% in Wednesday trading, reaching $19.68, despite significantly lower trading volume. The company's recent quarterly results surpassed analyst expectations with an adjusted EPS of $0.64 and revenue of $401.25 million, though revenue was down 34.3% year-over-year. Analyst sentiment is mixed, with an average price target of $25.06, indicating potential upside.
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline
Sarepta Therapeutics reported strong Q2 2026 financial results, including $328.7 million in net product revenue and both GAAP and non-GAAP operating income, driven by PMO and ELEVIDYS sales. The company also announced the appointment of Michael Severino as its new CEO, who will lead Sarepta's continued advancement of its rare disease pipeline, with key data readouts for DM1 and FSHD expected in H2 2026 and a new Huntington's disease program initiated. Despite a year-over-year revenue decrease attributed to an updated ELEVIDYS label and a missed milestone payment, Sarepta narrowed its 2026 revenue guidance to $1.2 billion to $1.3 billion and ended Q2 with a robust cash position of approximately $945 million.
Sarepta Posts US$328.7M Results
Sarepta Therapeutics Inc. (SRPT:NASDAQ) reported Q2 2026 product revenue of US$328.7 million, driven by PMO and ELEVIDYS sales, and announced Michael Severino as its new CEO. The company narrowed its 2026 revenue guidance to US$1.2 billion to US$1.3 billion and expects important data readouts for its DM1 and FSHD programs in the second half of 2026. Despite a decrease in total revenue compared to Q2 2025 due to updated ELEVIDYS labeling and the absence of a milestone payment, Sarepta maintains a strong balance sheet and an active pipeline for rare diseases.
GSA Capital Partners LLP Purchases New Holdings in Sarepta Therapeutics, Inc. $SRPT
GSA Capital Partners LLP has acquired a new stake in Sarepta Therapeutics (NASDAQ:SRPT), purchasing 103,618 shares valued at approximately $1.86 million, representing 0.10% of the company. Other institutional investors have also adjusted their holdings in SRPT, with institutional ownership collectively standing at 86.68%. Despite the stock's opening at $18.10, analysts hold a mixed view with an average "Hold" rating and a consensus price target of $25.06.
Sarepta Therapeutics (SRPT) Tightened 2026 Revenue Guidance, Is The Stock Still A Bargain?
Sarepta Therapeutics (SRPT) recently narrowed its 2026 revenue guidance to $1.2b to $1.3b, alongside positive second-quarter results and pipeline updates for rare disease programs. Despite a recent 7-day share price jump of 15.38%, the stock is still down 13.75% year-to-date and 83.87% over three years. Analysts currently peg Sarepta as 15.1% undervalued with a fair value of $21.65, but significant risks like safety concerns around ELEVIDYS and high R&D costs persist.
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research
Zacks Research has upgraded Sarepta Therapeutics (NASDAQ:SRPT) from a "strong sell" to a "hold" rating, contributing to a mixed analyst sentiment that results in an overall "Hold" consensus with a $25.06 price target. The company's shares opened at $18.42, with a market cap of $1.95 billion, and institutional investors hold a significant 86.68% stake. Several other analysts have adjusted their ratings and price targets, reflecting ongoing evaluation of the biopharmaceutical company focused on genetic medicines for rare neuromuscular diseases.
Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value
Sarepta Therapeutics, Inc. has filed a Form 13F as an institutional investment manager, detailing one information table entry with an aggregate reported value of $0. The filing, signed by Executive Vice President and CFO Ryan Wong, indicates no other included managers. This quarterly report provides a look into the company's reportable holdings, which in this instance amount to zero value.
Sarepta Therapeutics (SRPT) Tightened 2026 Revenue Guidance, Is The Stock Still A Bargain?
Sarepta Therapeutics recently tightened its 2026 revenue guidance to $1.2 billion to $1.3 billion and announced second-quarter results and pipeline updates. Despite a 15.38% share price jump over the last 7 days, the stock is down 13.75% year-to-date and 83.87% over three years. Analysts suggest a fair value of $21.65, indicating the stock is currently undervalued, but note ongoing safety concerns and high research costs as risks.
Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a beneficial ownership of 5,329,691 shares, or 5.05%, of Sarepta Therapeutics, Inc. common stock as of June 30, 2026. This reported amount includes 1,004,002 shares represented by Convertible Notes. Both entities share voting and dispositive power over a significant portion of these shares, with no sole voting or dispositive power.
Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom
Sarepta Therapeutics (SRPT) saw its flagship gene therapy, ELEVIDYS, experience a fifth consecutive quarterly revenue decline, with analysts from H.C. Wainwright & Co. reiterating a Sell rating and a $5.00 price target. Despite this, the market reaction was muted, suggesting investors are assigning significant value to the company's early-stage programs for myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), data for which are expected in the second half of 2026. The company's PMO franchise for Duchenne muscular dystrophy is stabilizing but faces future competitive pressure, and its cash position improved significantly in Q2 2026.
Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT
Bank of America Corp DE significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 26.6% in the first quarter, now owning over 2.15 million shares valued at approximately $46.7 million. This move is part of a broader trend of institutional investors, including several hedge funds, increasing their positions in the biotechnology company, with overall institutional ownership at 86.68%. Despite mixed analyst ratings, the consensus remains a "Hold" with a target price of $25.06, while the stock currently trades around $18.38.
Assenagon Asset Management S.A. Makes New $8.16 Million Investment in Sarepta Therapeutics, Inc. $SRPT
Assenagon Asset Management S.A. has initiated a new $8.16 million investment in Sarepta Therapeutics (NASDAQ:SRPT), acquiring 454,375 shares, which represents approximately 0.43% of the company. Institutional investors and hedge funds collectively own about 86.68% of SRPT. Despite mixed analyst ratings, with a consensus "Hold" and a target price of $25.06, the stock has recently traded between $14.68 and $25.32.
Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT
Dimensional Fund Advisors LP significantly reduced its stake in Sarepta Therapeutics, Inc. by selling 121,412 shares, leaving them with 336,736 shares valued at $7.3 million. Despite institutional investors owning a large portion of the company and some increasing their positions, analyst sentiment is mixed, resulting in a consensus "Hold" rating with an average price target of $25.06, against the stock's opening price of $17.18. Sarepta Therapeutics is a biopharmaceutical company focused on genetic medicines for rare neuromuscular diseases, particularly Duchenne muscular dystrophy.
Sarepta Therapeutics, Inc. (SRPT) Investor Outlook: Analyzing The 31.63% Potential Upside
Sarepta Therapeutics (SRPT) is a biotechnology firm focusing on RNA-targeted therapeutics and gene therapies for rare diseases like Duchenne muscular dystrophy, with a market capitalization of $1.77 billion. Despite a revenue decline of 34.30% and negative EPS, analysts project a 31.63% potential upside, driven by its innovative pipeline including EXONDYS 51, VYONDYS 53, AMONDYS 45, and gene therapies. Investors are weighing the significant growth potential against financial challenges and inherent biotech risks.
Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO
Sarepta Therapeutics' stock rose 12.9% despite cutting its 2026 revenue guidance and reporting weaker Q2 2026 results. The company appointed Michael Severino, M.D., as its new CEO, a move seen as a positive development due to his extensive biopharma background. The investment narrative now focuses on gene therapy execution, pipeline diversification, and managing safety concerns around its ELEVIDYS treatment.
Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO
Sarepta Therapeutics' stock rose 12.9% despite cutting its 2026 revenue guidance to US$1.20 billion–US$1.30 billion and reporting lower Q2 2026 revenue of US$401.25 million, alongside a net loss. The company appointed Michael Severino, M.D., as the new CEO, a move seen as a positive leadership change, and filed a US$39.73 million employee stock offering. The article suggests investors are weighing the impact of new leadership and pipeline diversification against current financial setbacks and safety concerns surrounding its gene therapy, ELEVIDYS.
Price to earnings forward of Sarepta Therapeutics, Inc. – BX:AB3A
This article provides financial data for Sarepta Therapeutics, Inc. under the ticker BX:AB3A on the BX Swiss exchange. It specifically highlights the "Price to earnings forward" metric for the company. The page appears to be a financial data snippet from TradingView, focusing on market data provided by ICE Data Services and FactSet.
Sarepta Therapeutics, Inc. Revenue Breakdown – BX:AB3A
Sarepta Therapeutics, Inc. (BX:AB3A) generated 1.74 billion CHF in revenue last year, primarily from its RNA-targeted Therapeutics, Small Interfering RNA Platform, Gene Therapy, and Other Genetic Therapeutic Modalities segment, which contributed 1.48 billion CHF. The United States was the largest regional contributor, accounting for 1.35 billion CHF of the total revenue.
Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer
Sarepta Therapeutics (SRPT) has appointed Michael Severino as its new Chief Executive Officer, bringing in a physician executive with extensive experience from major pharmaceutical companies. This leadership change occurs as Sarepta faces declining Q2 2026 revenues and has narrowed its full-year revenue guidance. Severino's focus will be on gene therapy execution, ELEVIDYS safety management, and balancing pipeline investment with cost control, with his initial impact expected to be evident in the Q3 2026 earnings report.
Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer
Sarepta Therapeutics has appointed Michael Severino as its new Chief Executive Officer and a member of its Board of Directors. Severino, with a strong background in senior leadership and research in biotech, joins the company as it navigates a revenue reset, with Q2 2026 revenue down and narrowed 2026 guidance. Investors will be closely watching Severino's approach to gene therapy execution, ELEVIDYS safety management, and resource allocation across various programs, with his first full quarter as CEO serving as a key indicator of his strategy.
State Street (NYSE: STT) discloses 8.4% Sarepta Therapeutics ownership via Schedule 13G
State Street Corporation and its affiliate SSGA Funds Management, Inc. have reported a significant beneficial ownership stake in Sarepta Therapeutics (SRPT) through a Schedule 13G filing. State Street and related entities beneficially own 8.4% of Sarepta's common stock, totaling 8,916,103 shares, with shared voting power over 8,642,126 shares. Separately, SSGA Funds Management, Inc. holds a 6% beneficial ownership, comprising 6,285,547 shares.
Sarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop
Sarepta Therapeutics (SRPT) shares rose 5% after its Q2 2026 earnings report, despite a significant revenue drop, due to the company reporting positive GAAP operating income and tightening its full-year guidance. Investors see this as confirmation of the company's path to profitability, transitioning from a single-product focus to a broader Duchenne-funding base. However, bears highlight ongoing concerns regarding capacity, safety events, and timing risks for ELEVIDYS, which could hinder revenue growth in the short term.
Empowered Funds LLC Has $2.48 Million Stake in Sarepta Therapeutics, Inc. $SRPT
Empowered Funds LLC significantly increased its stake in Sarepta Therapeutics (NASDAQ:SRPT) by 1,898,816.7% in Q1, holding 113,935 shares valued at $2.48 million. Other institutional investors also adjusted their positions, and collective institutional ownership stands at 86.68%. Despite the company beating Q2 earnings and revenue estimates, its revenue declined 34.3% year-over-year, leading to mixed analyst ratings and a consensus "Hold" with an average price target of $24.72.
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
Sarepta Therapeutics (SRPT) reported Q2 2026 adjusted earnings and total revenues that beat analyst estimates, despite a significant year-over-year decline in both figures, primarily due to lower Elevidys sales. The company updated its 2026 net product revenue guidance and raised its collaboration and other revenues forecast, while narrowing its combined R&D and SG&A expense guidance. Sarepta is also advancing key pipeline programs, including seeking full FDA approvals for Vyondys 53 and Amondys 45 and progressing studies for other muscular dystrophy treatments.
Sarepta’s new CEO Michael Severino faces critical milestones to prove growth
Sarepta Therapeutics' new CEO, Michael Severino, is navigating critical upcoming milestones that will determine the company's growth trajectory, including regulatory decisions for its Duchenne muscular dystrophy gene therapy Elevidys and exon-skipping treatments. Elevidys sales saw a sequential drop, though patient enrollment forms are increasing, and the company expects revenue improvements to lag until 2027. Severino also faces a pivotal FDA decision for Vyondys 53 and Amondys 45, and competition from Dyne Therapeutics' zeleciment rostudirsen.
Sarepta Narrows 2026 Revenue Guidance on Elevidys Q2 Sales Dip
Sarepta Therapeutics reported a 34 percent decline in Q2 2026 revenue, primarily due to lower sales of its Duchenne muscular dystrophy gene therapy, Elevidys, following an FDA label narrowing last year. Despite this, the company beat Wall Street's revenue and EPS estimates. Sarepta has narrowed its full-year 2026 revenue guidance to $1.2 billion to $1.3 billion and is studying Elevidys in a new setting to potentially re-expand its label.
Sarepta Therapeutics Q2 2026 Earnings Call Transcript
Sarepta Therapeutics reported strong financial performance in Q2 2026, with GAAP operating income of $13 million and non-GAAP operating income of $86 million, and cash and investments growing to $945 million. The company narrowed its 2026 net product revenue guidance to $1.2 billion-$1.3 billion but increased collaboration revenue guidance. Sarepta remains confident in its Duchenne muscular dystrophy franchise and its emerging siRNA pipeline, with key data readouts expected in late 2026 and early 2027.
Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market
Sarepta Therapeutics is facing an FDA clinical hold on its Duchenne muscular dystrophy (DMD) therapy, Elevidys, due to safety concerns over acute liver failure, even as the global DMD market is projected to reach US$62.13 billion by 2030. Despite the hold, Sarepta has five other FDA-approved DMD treatments and a pipeline focused on genetic medicines for rare diseases, including new CEO Michael Severino's equity awards tied to long-term performance. Analyst opinions on the stock are divided, with some maintaining Outperform ratings while others have downgraded or reiterated Sell ratings due to the safety issues and demand uncertainty.
Sarepta set to report earnings as new CEO faces ELEVIDYS test
Sarepta Therapeutics is poised to release its second-quarter earnings, with investors keenly observing the performance of its gene therapy ELEVIDYS under new CEO Michael Severino. The company faces scrutiny over whether ELEVIDYS sales can stabilize after a recent decline and safety concerns, impacting market sentiment and analyst ratings. The earnings call will provide the first opportunity for investors to hear Severino's plans for addressing challenges and driving growth.
Sarepta Therapeutics Inc expected to post earnings of 26 cents a share - Earnings Preview
Sarepta Therapeutics Inc is projected to report earnings of 26 cents per share. This information is based on an earnings preview from Refinitiv, indicating upcoming financial disclosures for the company.
Vanguard Portfolio Management (SRPT) discloses 8.05% beneficial stake in Sarepta
Vanguard Portfolio Management LLC has disclosed an 8.05% beneficial ownership stake in Sarepta Therapeutics Inc. (SRPT) through an amended Schedule 13G filing. As of June 30, 2026, Vanguard beneficially owns 8,499,421 shares, holding sole voting power over 121,951 shares and sole dispositive power over all 8,499,421 shares. This passive investment is held on behalf of various affiliated entities and managed accounts, with no single individual having more than a 5% interest within these holdings.
SRPT|Sarepta Therapeutics Inc|Price:15.560|Chg%:+0.025
This article
People on the Move: Michael Severino, M.D., Joins Sarepta Therapeutics as Chief Executive Officer
Michael Severino, M.D., has been appointed as the new Chief Executive Officer of Sarepta Therapeutics, a biopharmaceutical company specializing in precision genetic medicine for rare diseases. He succeeds Doug Ingram, who is retiring but will remain in an advisory role. Severino brings extensive experience from Tessera Therapeutics, AbbVie, and Amgen, and is expected to lead Sarepta in expanding its pipeline beyond Duchenne muscular dystrophy into other muscle, central nervous system, and cardiac diseases.
Sarepta Therapeutics (SRPT) Could Be 28% Below Fair Value As New CEO Takes Over
Sarepta Therapeutics (SRPT) has appointed Michael Severino, M.D., as its new CEO, effective July 28, 2026. Despite a recent modest share price gain, the stock has seen significant declines year-to-date and over the past five years. Analysts suggest SRPT could be 28.3% undervalued with a fair value of $21.65, but its current P/E ratio of 25.2x is above the US Biotechs average, raising concerns about its valuation.
BlackRock (NYSE: BLK) discloses 16.6M-share Sarepta Therapeutics (SRPT) position in 13G/A
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 16,642,620 shares of Sarepta Therapeutics Inc. common stock, which represents 15.8% of the outstanding class. The filing indicates BlackRock has sole voting power over 16,353,161 shares and sole dispositive power over all 16,642,620 shares. An iShares Core S&P Small-Cap ETF, managed by BlackRock, also holds more than five percent of Sarepta's outstanding common stock.
Sarepta Therapeutics (SRPT) Could Be 28% Below Fair Value As New CEO Takes Over
Sarepta Therapeutics (SRPT) has appointed Michael Severino as its new CEO, effective July 28, 2026. Despite recent share price declines, a valuation narrative suggests the stock is 28.3% undervalued with a fair value of $21.65, driven by its rare disease pipeline and potential new revenue streams. However, its current P/E ratio of 25.2x is higher than the industry average, and risks like persisting safety concerns for ELEVIDYS or administrative delays for gene therapies could impact its valuation.
Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to Decline
Sarepta Therapeutics (SRPT) is expected to report a significant year-over-year decline in Q2 earnings and revenues. While analysts have recently become more bullish on the company based on a higher Most Accurate Estimate, Sarepta's Zacks Rank of #4 makes a definitive prediction of an earnings beat difficult. Investors are advised to consider other factors beyond just earnings expectations for SRPT.
Sarepta Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
Sarepta Therapeutics (NASDAQ: SRPT) had approximately 843 employees worldwide as of March 2026, representing a 24.8% decline from 2023. Despite this reduction, the company is actively hiring, with 85 active job postings in 2026. The majority of its workforce is in the United States, and the average employee salary is $167,165.
Sarepta Therapeutics (SRPT) Brings In New CEO Severino Is Its R&D Strategy Entering a New Phase?
Sarepta Therapeutics has appointed Michael Severino, an R&D veteran, as its new CEO, combining his role with a seat on the board. This leadership change comes as Sarepta is focusing on the safety data of its drug ELEVIDYS, particularly regarding acute liver injury. Severino's expertise could influence Sarepta's prioritization of its gene therapy and RNA-based rare disease programs and reshape the company's investment narrative.
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
Sarepta Therapeutics has appointed Michael Severino, M.D. as its new Chief Executive Officer, effective July 28, 2026. Severino, formerly CEO of Tessera Therapeutics and Vice Chairman at AbbVie, will also join Sarepta's Board of Directors. He succeeds Doug Ingram, who is retiring but will serve in an advisory capacity until the end of 2026 to ensure a smooth transition.
Sarepta names Michael Severino, former Tessera CEO, as new chief executive
Sarepta Therapeutics, known for its Duchenne muscular dystrophy treatments, has appointed Michael Severino, former CEO of Tessera Therapeutics, as its new chief executive. Severino replaces Doug Ingram, who is retiring after nearly a decade. The company has faced scrutiny over the efficacy and safety of its treatments, and its share price has significantly declined since early 2025.
Sarepta Therapeutics Appoints Michael Severino as CEO
Sarepta Therapeutics has appointed Michael Severino as its new CEO and a Class I director, effective July 28, 2026. Severino replaces Doug Ingram, who is retiring but will remain an adviser for the rest of 2026. Severino's three-year contract includes a $1.18 million base salary and a significant $35 million sign-on equity package, highlighting Sarepta's focus on leadership stability in advancing its rare disease pipeline.
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has appointed Michael Severino, M.D., as its new Chief Executive Officer, effective July 28, 2026. Dr. Severino, previously CEO of Tessera Therapeutics, will also join Sarepta’s Board of Directors, succeeding retiring CEO Doug Ingram. He brings over 25 years of biopharmaceutical experience, including significant leadership roles at AbbVie and Amgen, and is expected to further advance Sarepta's work in precision genetic medicine for rare diseases.
SRPT|Sarepta Therapeutics Inc|Price:15.680|Chg%:-0.200
Sarepta Therapeutics Inc (SRPT) is a commercial-stage biopharmaceutical company focusing on RNA-targeted therapeutics and gene therapy for rare diseases like Duchenne muscular dystrophy. The company's fundamentals are considered healthy with high growth potential, and it is currently regarded as fairly valued. Analysts have given it a "Hold" rating with a target price of 22.593, indicating a potential upside despite a recent weak stock market performance.
Sarepta Therapeutics stock steadies as investors weigh Elevidys expansion and revenue trajectory
Sarepta Therapeutics (SRPT) stock reflects a balancing act where investors are weighing the growing revenue from its Elevidys gene therapy against persistent operating losses. The company's 2024 revenue reached $1.28 billion, with Elevidys emerging as a significant growth driver, yet net losses mounted to $1.1 billion due to heavy investment in R&D and commercial scaling. Despite these losses, a substantial cash position of $2.0 billion provides liquidity, but the company's valuation remains sensitive to clinical milestones, regulatory decisions, and the long-term potential of its Duchenne muscular dystrophy treatments.
SRPT: Sarepta Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas
This article provides the latest stock information for Sarepta Therapeutics Inc (SRPT), including its current price, market capitalization, and key financial metrics. Recent news highlights a 4% stock drop due to Citi flagging a potentially stronger rival in the Duchenne space, and the company is scheduled to announce its second-quarter 2026 financial results. The page also features trending discussions on other prominent stocks like GOOGL, SMCI, and RKLB.
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will announce its second quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, August 5, 2026. Following the announcement, the company will host a conference call at 4:30 p.m. E.T. to discuss the results, with a live webcast available on their investor relations website. Sarepta is a leader in precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy.
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will report its second-quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, August 5, 2026. Following the release, the company will host a conference call at 4:30 p.m. E.T. to discuss the results, with details available on their investor relations website.
Press Release: Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
Sarepta Therapeutics is scheduled to announce its second quarter 2026 financial results after the market closes on Wednesday, August 5, 2026. This announcement will be followed by a conference call and webcast with management to discuss the results and provide a business update. The event details, including access information for the webcast and replay, are provided.
